ArticlePharmacoEconomics - open2023

A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada.

Anuja Chatterjee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.